The known cases up to 2015 are discussed in a review article by Bučar, Lancaster, and Bernstein.
Dibenzoxazepines
Multidisciplinary studies involving experimental and computational approaches were applied to pharmaceutical molecules to facilitate the comparison of their solid-state structures. Specifically, this study has focused on exploring how changes in molecular structure affect the molecular conformation, packing motifs, interactions in the resultant crystal lattices and the extent of solid-state diversity of these compounds. The results highlight the value of crystal structure prediction studies and PIXEL calculations in the interpretation of the observed solid-state behaviour and quantifying the intermolecular interactions in the packed structures and identifying the key stabilising interactions. An experimental screen yielded 4 physical forms for clozapine as compared to 60 distinct physical forms for olanzapine. The experimental screening results of clozapine are consistent with its crystal energy landscape which confirms that no alternate packing arrangement is thermodynamically competitive to the experimentally obtained structure. Whilst in case of olanzapine, crystal energy landscape highlights that the extensive experimental screening has probably not found all possible polymorphs of olanzapine, and further solid form diversity could be targeted with a better understanding of the role of kinetics in its crystallisation. CSP studies were able to offer an explanation for the absence of the centrosymmetric dimer in anhydrous clozapine. PIXEL calculations on all the crystal structures of clozapine revealed that similar to olanzapine, the intermolecular interaction energy in each structure is also dominated by the Ed. Despite the molecular structure similarity between amoxapine and loxapine (molecules in group 2), the crystal packing observed in polymorphs of loxa differs significantly from the amoxapine. A combined experimental and computational study demonstrated that the methyl group in loxapine has a significant influence in increasing the range of accessible solid forms and favouring various alternate packing arrangements. CSP studies have again helped in explaining the observed solid-state diversity of loxapine and amoxapine. PIXEL calculations showed that in absence of strong H-bonds, weak H-bonds such as C–H...O, C–H...N and dispersion interactions play a key role in stabilising the crystal lattice of both the molecules. Efficient crystal packing of amoxapine seems to be contributing towards its monomorphic behaviour as compared to the comparatively less efficient packing of loxapine molecules in both polymorphs. The combination of experimental and computational approaches has provided a deeper understanding of the factors influencing the solid-state structure and diversity in these compounds. Hirshfeld surfaces using Crystal Explorer represent another way of exploring packing modes and intermolecular interactions in molecular crystals. The influence of changes in the small substituents on shape and electron distribution can also be investigated by mapping the total electron density on the electrostatic potential for molecules in the gas phase. This allows straightforward visualisation and comparison of overall shape, electron-rich and electron-deficient regions within molecules. The shape of these molecules can be further investigated to study its influence on diverse solid-state diversity.
Posaconazole
The original formulations of posaconazole on the market licensed as Noxafil were formulated utilising form I of posaconazole. The discovery of polymorphs of posaconazole increased rapidly and resulted in much research in crystallography of posaconazole. A methanol solvate and a 1,4-dioxane co-crystal were added to the Cambridge Structural Database (CSD).